Lombaard, Johan J.

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 625

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 625

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

Morales-Ramirez, J., Bogner, J. R., Molina, J.-M., Lombaard, J., Dicker, I. B., Stock, D. A., DeGrosky, M., Gartland, M., Pene Dumitrescu, T., Min, S., et al. (2018) · PLOS ONE

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 44